会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明公开
    • DEVICE FOR VIBRATING A STRINGED INSTRUMENT
    • VORRICHTUNG ZUM VIBRIEREN EINES SAITENINSTRUMENTS
    • EP3010012A1
    • 2016-04-20
    • EP14810128.0
    • 2014-06-06
    • Kobayashi, KojiKobayashi, Shoji
    • KOBAYASHI, Koji
    • G10D3/00G10D3/02G10H1/045H04R1/02
    • Provided is a device (20) for vibrating a string instrument (1) to allow the string instrument to be used as a loudspeaker. To press a base member (22) fitted with a vibration generator (50) against a bridge (13) of the string instrument (1) via a load point member (24) of a vibration transmission member (26), the base member (22) is provided with a fulcrum member (30) engaging an upper side of the strings (9) of the string instrument (1) and an anchor member (38) engaging a lower side of the strings (9). In order to urge the vibration transmission member (26) against the bridge (13), a cam mechanism (40) presses the anchor member (38) against the lower side of the strings (9).
    • 本发明提供了一种用于使琴弦乐器(1)振动以允许琴弦乐器用作扬声器的装置(20)。 为了通过振动传递部件(26)的负载点部件(24)将装配有振动发生器(50)的基部部件(22)压靠在弦乐器(1)的桥架(13)上, 22)设置有与弦乐器(1)的弦(9)的上侧接合的支点构件(30)和与琴弦(9)的下侧接合的定位构件(38)。 为了将振动传递构件(26)推靠在桥(13)上,凸轮机构(40)将锚定构件(38)压靠在绳(9)的下侧。
    • 6. 发明申请
    • PROLINE DERIVATIVE
    • WO1993013065A1
    • 1993-07-08
    • PCT/JP1992001711
    • 1992-12-25
    • JAPAN TOBACCO INC.KOBAYASHI, Koji;ABE, Hiroyuki;TOIDE, Katsuo;UCHIDA, Itsuo;
    • JAPAN TOBACCO INC.
    • C07D207/08
    • C07D207/08C07D207/16C07D401/14C07D403/12C07D403/14C07D407/14C07D417/06C07D417/14Y02P20/55
    • A proline derivative represented by general formula (I), wherein A represents -O-, -CHR - or -NR - wherein R represents hydrogen or heterocycle and R represents lower alkoxycarbonyl-lower alkyl; W represents phenyl which may be substituted by halogen, lower alkyl or lower alkoxy, adamantyl, lower alkyl or heterocycle; U represents -O-, -S-, -NH- or -CHR - wherein R represents hydrogen or lower alkoxycarbonyl; X represents -S-, -SO-, -SO2-, -O- or -NH-; D represents benzene or heterocycle; and Y and Z may be the same or different from each other and represent each hydrogen, halogen, optionally fluorinated lower alkyl, amino, nitro, hydroxy or lower alkoxy. This derivative has a specifically potent inhibitory activity against prolyl endopeptidase and inhibits the decomposition and inactivation of TRH, substance P, neurotensin, vasopressin, etc. Therefore, it can be used for preventing and/or treating dementia including Alzheimer's disease and amnesia.
    • 由通式(I)表示的脯氨酸衍生物,其中A表示-O-,-CHR 1 - 或-NR 2 - ,其中R 1表示氢或杂环,R 2表示低级烷氧基羰基 - 低级 烷基; W表示可被卤素,低级烷基或低级烷氧基,金刚烷基,低级烷基或杂环取代的苯基; U表示-O - , - S - , - NH-或-CHR 5 - ,其中R 5表示氢或低级烷氧基羰基; X表示-S - , - SO - , - SO 2 - , - O-或-NH-; D表示苯或杂环; Y和Z可以相同或不同,表示各个氢,卤素,任选氟化的低级烷基,氨基,硝基,羟基或低级烷氧基。 该衍生物对脯氨酰内肽酶具有特异性的抑制活性,抑制TRH,物质P,神经丝氨酸,加压素等的分解和失活。因此,它可用于预防和/或治疗痴呆,包括阿尔茨海默病和遗忘症。
    • 9. 发明申请
    • PATTERN EXTRACTION APPARATUS
    • 图案提取装置
    • WO1998020454A1
    • 1998-05-14
    • PCT/JP1996003212
    • 1996-11-01
    • YAMATAKE-HONEYWELL CO., LTD.KOBAYASHI, KojiNAKAJIMA, HiroshiAOKI, TakafumiKAWAMATA, MasayukiHIGUCHI, Tatsuo
    • YAMATAKE-HONEYWELL CO., LTD.
    • G06T07/00
    • G06K9/522
    • The collation Fourier image data (Fig. 1D) FB, which is the two-dimensional discrete Fourier transform (DFT) of image data (Fig. 1C) of a collation pattern, is combined with the two-dimensional DFT of registered Fourier image data (Fig. 1B) FA, and the resultant data is processed for amplitude limitation and for its two-dimensional DFT. A correlation peak is extracted from correlation components appearing in the data (Fig. 1E) of the combined two-dimensional DFT, and a predetermined region including this correlation peak is masked (Fig. 1F). The masked image data is processed to obtain its two-dimensional inverse DFT with the amplitude restored, then combined again with the registered Fourier image data FA, and processed to determine its two-dimensional inverse DFT. Consequently, image data including a different pattern or a transferred pattern are obtained as shown in Fig. 1G.
    • 作为核对图案的图像数据(图1C)的二维离散付里叶变换(DFT)的核对付里叶图像数据(图1D)FB与登记的付里叶图像数据的二维DFT组合 (图1B)FA,并且对于幅度限制和其二维DFT处理所得数据。 从出现在组合的二维DFT的数据(图1E)中的相关分量中提取相关峰值,并且包括该相关峰值的预定区域被屏蔽(图1F)。 对掩蔽的图像数据进行处理以获得其恢复幅度的二维逆DFT,然后再次与注册的付里叶图像数据FA组合,并进行处理以确定其二维逆DFT。 因此,获得包括不同图案或转印图案的图像数据,如图3所示。 1G。
    • 10. 发明申请
    • DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND INTERMEDIATES THEREOF, MEDICINAL USE OF THE SAME, AND PROCESSES FOR PRODUCING THE SAME
    • DIAZABICYCLO [3.3.1]非衍生物及其中间体,其药物用途及其生产方法
    • WO1996030372A1
    • 1996-10-03
    • PCT/JP1996000742
    • 1996-03-21
    • JAPAN TOBACCO INC.KOBAYASHI, KojiORITA, KazuhiroHAMADA, AtsushiINABA, TakashiABE, HiroyukiMIYAZAKI, Susumu
    • JAPAN TOBACCO INC.
    • C07D471/08
    • C07D471/08
    • Diazabicyclo[3.3.1]nonane derivatives represented by general formula (1), wherein R represents -CONH-(CHR )m-R (wherein R represents hydrogen or alkyl; m is 0, 1 or 2; and R represents optionally substituted aryl, optionally substituted heterocycle, optionally substituted cycloalkyl, alkyl or alkyenyl) or -CO-R [wherein R represents alkyl, aralkyloxy or -NR R {wherein R and R are the same or different and each represents alkyl, or R and R together with the nitrogen atom to which they are bonded from a group (a) (wherein n is 2 or 3)}]; interm ediates thereof; and a nicotinic cholinergic agent containing the diazabicyclo[3.3.1]nonane derivatives. The compounds have a nicotinic cholinergic effect and a dopamine-releasing effect and are usable as a remeddy for dementia such as Alzheimer's disease, a drug for relieving memory disorders, a remedy for central nerve degeneration diseases, and a drug for relieving cerebral function disorders.
    • 由通式(1)表示的二氮杂双环[3.3.1]壬烷衍生物,其中R表示-CONH-(CHR 1)m R 2(其中R 1表示氢或烷基; m是0,1或2 ; R 2代表任选取代的芳基,任选取代的杂环,任选取代的环烷基,烷基或烷基)或-CO-R 3 [其中R 3表示烷基,芳烷氧基或-NR 4 R 5 >其中R 4和R 5相同或不同,并且各自代表烷基,或者R 4和R 5与它们所连接的氮原子一起(a)(其中 n为2或3)}]; 其间; 和含有二氮杂双环[3.3.1]壬烷衍生物的烟碱型胆碱能药剂。 所述化合物具有烟碱性胆碱能作用和多巴胺释放作用,并且可用作痴呆症的补救剂,例如阿尔茨海默氏病,用于缓解记忆障碍的药物,用于中枢神经变性疾病的药物,以及用于缓解脑功能障碍的药物。